NCIMMUNE LEADING EARLY CANCER DETECTION

This area of the website contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules. This information is not directed to nor is it intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

overview

Oncimmune is a leading early cancer detection company, developing and commercialising its proprietary EarlyCDT® platform technology. The Group has pioneered the development of tests based on the presence in the blood of autoantibodies against specific tumour associated antigens (TAAs) that have the potential to detect cancer up to four years earlier than other methods such as a chest X-ray or Spiral CT and can be applied to a very wide range of solid tumour types.

In 2009, Oncimmune launched its first test, EarlyCDT®Lung, which was test-marketed until 2012, at which time it launched its EarlyCDT-Lung test nationally across the US. It is now available through physicians in the US and privately in the UK and other regions.

EarlyCDTLung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in moderate and high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy.  EarlyCDT tests for liver and ovarian cancer are in final validation.

Oncimmune Holdings Plc was incorporated in England and Wales and its main country of operation is England.

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept